|
1.
|
Li XY, Guo X, Feng S, et al: Relationship
between a family history of malignancy and the incidence of
laryngeal carcinoma in the Liaoning province of China. Clin
Otolaryngol. 34:127–131. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar
|
|
3.
|
Loyo M and Pai SI: The molecular genetics
of laryngeal cancer. Otolaryngol Clin North Am. 41:v657–v672. 2008.
View Article : Google Scholar
|
|
4.
|
Hoffman HT, Porter K, Karnell LH, et al:
Laryngeal cancer in the United States: changes in demographics,
patterns of care, and survival. Laryngoscope. 116:1–13. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Neel BG, Gu H and Pao L: The ‘Shp’ing
news: SH2 domain-containing tyrosine phosphatases in cell
signaling. Trends Biochem Sci. 28:284–293. 2003.
|
|
6.
|
Lai LA, Zhao C, Zhang EE and Feng GS: The
Shp-2 tyrosine phosphatase. Protein Phosphatases. Arino J and
Alexander D: Springer-Verlag; Berlin, Heidelberg: pp. 275–299.
2004, View Article : Google Scholar
|
|
7.
|
Tartaglia M and Gelb BD: Germ-line and
somatic PTPN11 mutations in human disease. Eur J Med Genet.
48:81–96. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Bentires-Alj M, Gil SG, Chan R, et al: A
role for the scaffolding adapter GAB2 in breast cancer. Nat Med.
12:114–121. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Higuchi M, Tsutsumi R, Higashi H and
Hatakeyama M: Conditional gene silencing utilizing the lac
repressor reveals a role of SHP-2 in cagA-positive Helicobacter
pylori pathogenicity. Cancer Sci. 95:442–447. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Higashi H, Tsutsumi R, Muto S, et al:
SHP-2 tyrosine phosphatase as an intracellular target of
Helicobacter pylori CagA protein. Science. 295:683–686.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Takahashi A, Tsutsumi R, Kikuchi I, et al:
SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor
suppressor to an oncogenic driver. Mol Cell. 43:45–56. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Chan RJ and Feng GS: PTPN11 is the first
identified proto-oncogene that encodes a tyrosine phosphatase.
Blood. 109:862–867. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Wen W, Han T, Chen C, et al: Cyclin G1
expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR
signaling. Mol Cancer Ther. 12:1796–1804. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Broich G, Lavezzi AM, Biondo B and
Pignataro LD: PCNA - a cell proliferation marker in vocal cord
cancer. Part II: recurrence in malignant laryngeal lesions. In
Vivo. 10:175–178. 1996.PubMed/NCBI
|
|
15.
|
Dobrossy L: Epidemiology of head and neck
cancer: magnitude of the problem. Cancer Metastasis Rev. 24:9–17.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Manes S, Mira E, Gomez-Mouton C, Zhao ZJ,
Lacalle RA and Martinez AC: Concerted activity of tyrosine
phosphatase SHP-2 and focal adhesion kinase in regulation of cell
motility. Mol Cell Biol. 19:3125–3135. 1999.PubMed/NCBI
|
|
17.
|
Tartaglia M, Mehler EL, Goldberg R, et al:
Mutations in PTPN11, encoding the protein tyrosine phosphatase
SHP-2, cause Noonan syndrome. Nat Genet. 29:465–468. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Aceto N, Sausgruber N, Brinkhaus H, et al:
Tyrosine phosphatase SHP2 promotes breast cancer progression and
maintains tumor-initiating cells via activation of key
transcription factors and a positive feedback signaling loop. Nat
Med. 18:529–537. 2012. View
Article : Google Scholar
|
|
19.
|
Grossmann KS, Rosario M, Birchmeier C and
Birchmeier W: The tyrosine phosphatase Shp2 in development and
cancer. Adv Cancer Res. 106:53–89. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Cunnick JM, Meng S, Ren Y, et al:
Regulation of the mitogen-activated protein kinase signaling
pathway by SHP2. J Biol Chem. 277:9498–9504. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Dittrich A, Quaiser T, Khouri C, Gortz D,
Monnigmann M and Schaper F: Model-driven experimental analysis of
the function of SHP-2 in IL-6-induced Jak/STAT signaling. Mol
Biosyst. 8:2119–2134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Tseng PC, Huang WC, Chen CL, et al:
Regulation of SHP2 by PTEN/AKT/GSK-3beta signaling facilitates
IFN-gamma resistance in hyperproliferating gastric cancer.
Immunobiology. 217:926–934. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Chan G, Kalaitzidis D and Neel BG: The
tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis
Rev. 27:179–192. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Feng GS: Shp2-mediated molecular signaling
in control of embryonic stem cell self-renewal and differentiation.
Cell Res. 17:37–41. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Wu R, Duan L, Ye L, et al: S100A9 promotes
the proliferation and invasion of HepG2 hepatocellular carcinoma
cells via the activation of the MAPK signaling pathway. Int J
Oncol. 42:1001–1010. 2013.PubMed/NCBI
|
|
26.
|
Chung EJ, Urick ME, Kurshan N, et al:
MEK1/2 inhibition enhances the radiosensitivity of cancer cells by
downregulating survival and growth signals mediated by EGFR
ligands. Int J Oncol. 42:2028–2036. 2013.PubMed/NCBI
|
|
27.
|
Pradier R, Gonzalez A, Matos E, et al:
Prognostic factors in laryngeal carcinoma. Experience in 296 male
patients. Cancer. 71:2472–2476. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Jin YT, Kayser S, Kemp BL, et al: The
prognostic significance of the biomarkers p21WAF1/CIP1,
p53, and bcl-2 in laryngeal squamous cell carcinoma. Cancer.
82:2159–2165. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Tandon S, Tudur-Smith C, Riley RD, Boyd MT
and Jones TM: A systematic review of p53 as a prognostic factor of
survival in squamous cell carcinoma of the four main anatomical
subsites of the head and neck. Cancer Epidemiol Biomarkers Prev.
19:574–587. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Fujii S, Uryu H, Akashi K, et al: Clinical
significance of KRAS gene mutation and epidermal growth factor
receptor expression in Japanese patients with squamous cell
carcinoma of the larynx, oropharynx and hypopharynx. Int J Clin
Oncol. 118:454–463. 2013. View Article : Google Scholar : PubMed/NCBI
|
